Pfizer Anticipates ‘Fair’ Share Of Adalimumab Market In US
Company Expects To Use Interchangeability Designation To Its Advantage
Pfizer expects to make significant strides in the adalimumab market once it launches its Humira biosimilar late next year, but may not be able to enjoy its anticipated interchangeability designation until 2024.
You may also be interested in...
Remission rates with existing therapies leave much room for improvement, so a variety of treatments are needed – leaving major players attempting to carve unique paths in a crowded market.
Pfizer appears to be maintaining its “opportunistic” approach to biosimilars, having ceased to split out the business unit’s results during its Q3 earnings report.
Looking back over the second quarter of 2022, Generics Bulletin executive editor Dave Wallace picks out highlights from April to June that include multiple first generic and biosimilar launches, some noteworthy executive moves, further preparation for biosimilar competition to Humira in the US, and a major European industry conference.